719 related articles for article (PubMed ID: 36282501)
1. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Clinical Outcomes and Imaging Features in Hospitalized Patients with SARS-CoV-2 Omicron Subvariants.
Lee JE; Hwang M; Kim YH; Chung MJ; Jeong WG; Sim BH; Jeong YJ
Radiology; 2023 Jul; 308(1):e230653. PubMed ID: 37462497
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.
Lewnard JA; Hong VX; Patel MM; Kahn R; Lipsitch M; Tartof SY
Nat Med; 2022 Sep; 28(9):1933-1943. PubMed ID: 35675841
[TBL] [Abstract][Full Text] [Related]
4. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
JAMA Netw Open; 2023 Feb; 6(2):e231181. PubMed ID: 36853602
[TBL] [Abstract][Full Text] [Related]
5. Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes.
Mondi A; Mastrorosa I; Piselli P; Cimaglia C; Matusali G; Carletti F; Giannico G; Milozzi E; Biliotti E; Di Bari S; Chinello P; Beccacece A; Faraglia F; Vittozzi P; Mosti S; Tetaj N; Stazi GV; Pinnetti C; Camici M; D'Annunzio A; Marani A; Fabeni L; Specchiarello E; Gruber CEM; Villanacci A; Minicucci S; Garbuglia AR; Ianniello S; Marchioni L; Taglietti F; D'Offizi G; Palmieri F; Nicastri E; Maggi F; Vaia F; Girardi E; Antinori A
J Med Virol; 2023 Jun; 95(6):e28831. PubMed ID: 37246793
[TBL] [Abstract][Full Text] [Related]
6. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
[TBL] [Abstract][Full Text] [Related]
7. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38761806
[TBL] [Abstract][Full Text] [Related]
8. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
Nakakubo S; Kishida N; Okuda K; Kamada K; Iwama M; Suzuki M; Yokota I; Ito YM; Nasuhara Y; Boucher RC; Konno S
Lancet Infect Dis; 2023 Nov; 23(11):1244-1256. PubMed ID: 37399831
[TBL] [Abstract][Full Text] [Related]
9. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
10. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada.
Russell SL; Klaver BRA; Harrigan SP; Kamelian K; Tyson J; Hoang L; Taylor M; Sander B; Mishra S; Prystajecky N; Janjua NZ; Zlosnik JEA; Sbihi H
J Med Virol; 2023 Jan; 95(1):e28423. PubMed ID: 36546412
[TBL] [Abstract][Full Text] [Related]
11. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
Nazmunnahar ; Ahmed I; Islam MR
Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
Viruses; 2023 May; 15(6):. PubMed ID: 37376600
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants.
Ali KM; Rashid PMA; Ali AM; Tofiq AM; Salih GF; Dana OI; Rostam HM
Eur J Clin Invest; 2023 Sep; 53(9):e14004. PubMed ID: 37036255
[TBL] [Abstract][Full Text] [Related]
14. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.
Sarkar A; Omar S; Alshareef A; Fanous K; Sarker S; Alroobi H; Zamir F; Yousef M; Zakaria D
Hum Vaccin Immunother; 2023 Dec; 19(1):2212568. PubMed ID: 37254497
[TBL] [Abstract][Full Text] [Related]
15. Nursing and healthcare-associated pneumonia due to SARS-CoV-2 Omicron variant.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
Respir Investig; 2024 Mar; 62(2):252-257. PubMed ID: 38241958
[TBL] [Abstract][Full Text] [Related]
16. Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
Beraud G; Bouetard L; Civljak R; Michon J; Tulek N; Lejeune S; Millot R; Garchet-Beaudron A; Lefebvre M; Velikov P; Festou B; Abgrall S; Lizatovic IK; Baldolli A; Esmer H; Blanchi S; Froidevaux G; Kapincheva N; Faucher JF; Duvnjak M; Afşar E; Švitek L; Yarimoglu S; Yarimoglu R; Janssen C; Epaulard O;
Clin Microbiol Infect; 2023 May; 29(5):642-650. PubMed ID: 36587737
[TBL] [Abstract][Full Text] [Related]
17. As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
Xu R; Wang W; Zhang W
Front Public Health; 2022; 10():1039123. PubMed ID: 36504951
[TBL] [Abstract][Full Text] [Related]
18. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants.
Esper FP; Adhikari TM; Tu ZJ; Cheng YW; El-Haddad K; Farkas DH; Bosler D; Rhoads D; Procop GW; Ko JS; Jehi L; Li J; Rubin BP
J Infect Dis; 2023 Feb; 227(3):344-352. PubMed ID: 36214810
[TBL] [Abstract][Full Text] [Related]
19. Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent.
Pascall DJ; Vink E; Blacow R; Bulteel N; Campbell A; Campbell R; Clifford S; Davis C; da Silva Filipe A; El Sakka N; Fjodorova L; Forrest R; Goldstein E; Gunson R; Haughney J; Holden MTG; Honour P; Hughes J; James E; Lewis T; MacLean O; McHugh M; Mollett G; Nyberg T; Onishi Y; Parcell B; Ray S; Robertson DL; Seaman SR; Shabaan S; Shepherd JG; Smollett K; Templeton K; Wastnedge E; Wilkie C; Williams T; ; Thomson EC
J Infect; 2023 Aug; 87(2):128-135. PubMed ID: 37270070
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes.
Ambrose N; Amin A; Anderson B; Barrera-Oro J; Bertagnolli M; Campion F; Chow D; Danan R; D'Arinzo L; Drews A; Erlandson K; Fitzgerald K; Garcia M; Gaspar FW; Gong C; Hanna G; Jones S; Lopansri B; Musser J; O'Horo J; Piantadosi S; Pritt B; Razonable RR; Roberts S; Sandmeyer S; Stein D; Vahidy F; Webb B; Yttri J
JAMA Netw Open; 2023 Apr; 6(4):e239694. PubMed ID: 37093599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
